【New Stock IPO】Biotech Startup Earendil Labs Reportedly Plans Hong Kong Listing with Potential Fundraising Up to 3.9 Billion Yuan

SocialAnxietyStaker · 2026-03-13T07:50:27+00:00

Biotech startup Earendil Labs is considering listing in Hong Kong, with plans to raise up to $500 million. Earendil focuses on using AI technology for drug discovery and has already partnered with several renowned pharmaceutical companies, including Sanofi and Wuxi AppTec.

SocialAnxietyStaker

2026-03-13 07:50:27

Abstract generation in progress

Biotech startup Earendil Labs, which uses artificial intelligence (AI) for drug discovery, is reportedly considering an IPO in Hong Kong. Bloomberg cited sources saying Earendil may raise up to $500 million (HKD 3.9 billion) and is working with China International Capital Corporation and Morgan Stanley to arrange the offering.

Earendil, headquartered in Delaware, USA, is an affiliate of Beijing Huashen Zhiyao. The company focuses on biopharmaceutical research and development by integrating machine learning, generative protein engineering, and high-throughput experimental techniques.

Earendil has collaborations with pharmaceutical giants like Sanofi of France, including a partnership announced in January for autoimmune and inflammatory diseases. Last month, Earendil also reached an agreement with WuXi Biologics (02269) on cancer therapy technology, and this past Thursday, it announced another collaboration with WuXi Biologics (02269).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes